You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Constellation Pharma teams up with Genentech

Continue reading below

Constellation Pharmaceuticals Inc. said that it has entered into a major strategic agreement with Genentech, a California-based member of the Roche Group, to launch a broad collaboration based on the science of epigenetics and chromatin biology to discover and develop treatments for cancer and other serious diseases.

Under the agreement, Cambridge-based Constellation said it will receive committed funding of $95 million, comprising of an upfront payment and research funding for a three-year period. Constellation said it will be eligible for development and commercialization milestone payments as well as up to double-digit royalties on commercial sales of multiple products by Genentech.

Constellation’s press release also noted that Genentech has a future option to acquire all outstanding shares of Constellation based on pre-negotiated terms, which include a significant initial acquisition payment plus contingent value rights payments based on the future successful development and commercialization of multiple products by Genentech.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week